- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04908722
A Study to Evaluate Dose Levels of Ad26.COV2.S Administered as a Two-dose Schedule in Healthy Adults
October 11, 2023 updated by: Janssen Vaccines & Prevention B.V.
A Randomized, Double-blind, Phase 3 Study to Evaluate 6 Dose Levels of Ad26.COV2.S Administered As a Two-Dose Schedule in Healthy Adults
The purpose of this study is to demonstrate non-inferiority (NI) in terms of humoral immune responses after 6 dose levels of Ad26.COV2.S.
Study Overview
Study Type
Interventional
Enrollment (Actual)
1609
Phase
- Phase 3
Expanded Access
No longer available outside the clinical trial.
See expanded access record.
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Belo Horizonte, Brazil, 30150-221
- Santa Casa de Misericórdia de Belo Horizonte
-
Belo Horizonte, Brazil, 30130-100
- Universidade Federal De Minas Gerais - Hospital das Clínicas
-
Boa Vista, Brazil, 69304-415
- CECOR - Centro Oncológico de Roraima
-
Campinas, Brazil, 13060-904
- Sociedade Campineira de Educacao e Instrucao - Hospital e Maternidade Celso Pierro
-
Ceará, Brazil, 60430-160
- Núcleo de Medicina Tropical - Universidade Federal do Ceará
-
Criciúma, Brazil, 88811-508
- Sociedade Literaria e Caritativa Santo Agostinho - Hospital Sao Jose
-
Natal, Brazil, 59025-050
- Centro de Estudos e Pesquisas em Moléstias Infecciosas - CEPCLIN
-
Ribeirao Preto, Brazil, 14048-900
- Hospital das Clínicas da Faculdade de Medicina de RPUSP - HCRP
-
Rio de Janeiro, Brazil, 26030-380
- Municipio de Nova Iguacu - Hospital Geral de Nova Iguacu
-
Sao Paulo, Brazil, 04121-000
- Centro de Referência e Treinamento DST/AIDS
-
São Paulo, Brazil, 01228-000
- CPQuali Pesquisa Clinica LTDA ME
-
-
-
-
-
Berlin, Germany, 10787
- Klinische Forschung Berlin-Mitte GmbH
-
Hamburg, Germany, 22143
- Clinical Research HamburggmbH
-
Hannover, Germany, 30159
- Klinische Forschung Hannover-Mitte GmbH
-
Leipzig, Germany, 04103
- Synexus Clinical Research GmbH
-
Rostock, Germany, 18057
- Universitaetsmedizin Rostock
-
-
-
-
-
Gdansk, Poland, 80-542
- Gdanskie Centrum Zdrowia
-
Rzeszow, Poland, 35-055
- Centrum Medyczne Medyk
-
Skorzewo, Poland, 60-185
- Centrum Medyczne Pratia Poznan
-
-
-
-
-
Cape Town, South Africa, 7130
- Synexus Helderberg Clinical Research Centre
-
Dennilton, South Africa, 0485
- Ndlovu Elandsdoorn Site
-
Mamelodi East, South Africa, 122
- Stanza Clinical Research Centre : Mamelodi
-
Port Elizabeth, South Africa, 6001
- Phoenix Pharma (Pty) Ltd
-
Pretoria, South Africa, 0002
- Gct Sunnyside
-
Soshanguve, South Africa, 152
- Setshaba Research Centre
-
-
-
-
Arkansas
-
Little Rock, Arkansas, United States, 72205
- Baptist Health Center for Clinical Research
-
-
California
-
Anaheim, California, United States, 92801
- Anaheim Clinical Trials, LLC
-
Long Beach, California, United States, 90815
- Ark Clinical Research
-
Redding, California, United States, 96001
- Paradigm Clinical Research Centers, Inc.
-
San Diego, California, United States, 92120
- Wr-McCr, Llc
-
Tustin, California, United States, 92780
- Ark Clinical Research
-
-
Florida
-
Hallandale Beach, Florida, United States, 33009
- Velocity Clinical Research, Hallandale Beach
-
Miami, Florida, United States, 33179
- Floridian Research Institute
-
-
Louisiana
-
Metairie, Louisiana, United States, 70006
- MedPharmics, LLC
-
-
Nevada
-
Las Vegas, Nevada, United States, 89106
- Clinical Research Center of Nevada
-
-
New York
-
Rochester, New York, United States, 14609
- Rochester Clinical Research, Inc
-
-
North Carolina
-
Raleigh, North Carolina, United States, 27612
- Wake Research Associates
-
Wilmington, North Carolina, United States, 28403
- Trial Management Associates, LLC
-
-
Oklahoma
-
Yukon, Oklahoma, United States, 73099
- Tekton Research Inc.
-
-
South Carolina
-
North Charleston, South Carolina, United States, 29405
- Coastal Carolina Research Center
-
-
Texas
-
Keller, Texas, United States, 76248
- Ventavia Research Group, LLC
-
Plano, Texas, United States, 75093
- Research Your Health
-
-
Virginia
-
Richmond, Virginia, United States, 23226
- Clinical Research Partners, LLC
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 55 years (Adult)
Accepts Healthy Volunteers
Yes
Description
Inclusion Criteria:
- Participant must sign an informed consent form (ICF) indicating that he or she understands the purpose, procedures and potential risks and benefits of the study, and is willing to participate in the study
- Participant must be healthy, in the investigator's clinical judgment, as confirmed by medical history, physical examination, and vital signs performed at screening. Participant may have underlying illnesses, as long as the symptoms and signs are medically controlled and not considered to be comorbidities related to an increased risk of severe Coronavirus disease 2019 (COVID-19), except for smoking, which is allowed. If on medication for a condition, the medication dose must have been stable for at least 12 weeks preceding vaccination and expected to remain stable for the duration of the study. Participant will be included on the basis of physical examination, medical history, and vital signs
- All female participants of childbearing potential must: a) have a negative highly sensitive urine pregnancy test at screening; b) have a negative highly sensitive urine pregnancy test immediately prior to each study vaccine administration
- Participant agrees to not donate bone marrow, blood, and blood products from the first study vaccine administration until 3 months after receiving the last dose of study vaccine
- Participant must be willing to provide verifiable identification, has means to be contacted and to contact the investigator during the study
Exclusion Criteria:
- Participant has a clinically significant acute illness (this does not include minor illnesses such as diarrhea or mild upper respiratory tract infection) or temperature greater than or equal to (>=) 38.0 degree Celsius (C) (100.4 degree Fahrenheit [F]) within 24 hours prior to the planned first dose of study vaccine; randomization at a later date is permitted at the discretion of the investigator and after consultation with the sponsor
- Participant has a known or suspected allergy or history of anaphylaxis or other serious adverse reactions to vaccines or their excipients (including specifically the excipients of the study vaccine)
- Participant received or plans to receive: (a) licensed live attenuated vaccines - within 28 days before or after planned administration of the first or subsequent study vaccinations; and (b) other licensed (not live) vaccines - within 14 days before or after planned administration of the first or subsequent study vaccinations
- Participant received an investigational drug (including investigational drugs for prophylaxis of COVID-19) or used an invasive investigational medical device within 30 days or received investigational immunoglobulin (Ig) or monoclonal antibodies within 3 months, or received convalescent serum for COVID-19 treatment within 4 months or received an investigational vaccine within 6 months before the planned administration of the first dose of study vaccine or is currently enrolled or plans to participate in another investigational study during the course of this study
- Participant previously received a coronavirus vaccine
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Group 1: Ad26.COV2.S Dose Level 1
Participants in the main study and sub study will receive intramuscular (IM) injections of Ad26.COV2.S as a 2-dose vaccination regimen at dose level 1 on Days 1 and 57.
|
Participants will receive intramuscular (IM) injections of Ad26.COV2.S.
Other Names:
|
Experimental: Group 2: Ad26.COV2.S Dose Level 2
Participants will receive IM injections of Ad26.COV2.S as a 2-dose vaccination regimen at dose level 2 on Days 1 and 57 in the main study.
|
Participants will receive intramuscular (IM) injections of Ad26.COV2.S.
Other Names:
|
Experimental: Group 3: Ad26.COV2.S Dose Level 3
Participants in the main study and sub study will receive IM injections of Ad26.COV2.S as a 2-dose vaccination regimen at dose level 3 on Days 1 and 57.
|
Participants will receive intramuscular (IM) injections of Ad26.COV2.S.
Other Names:
|
Experimental: Group 4: Ad26.COV2.S Dose Level 4
Participants will receive IM injections of Ad26.COV2.S as a 2-dose vaccination regimen at dose level 4 on Days 1 and 57 in the main study.
|
Participants will receive intramuscular (IM) injections of Ad26.COV2.S.
Other Names:
|
Experimental: Group 5: Ad26.COV2.S Dose Level 5
Participants in the main study and sub study will receive IM injections of Ad26.COV2.S as a 2-dose vaccination regimen at dose level 5 on Days 1 and 57.
|
Participants will receive intramuscular (IM) injections of Ad26.COV2.S.
Other Names:
|
Experimental: Group 6: Ad26.COV2.S Dose Level 6
Participants in the main study and sub study will receive IM injections of Ad26.COV2.S as a 2-dose vaccination regimen at dose level 6 on Days 1 and 57.
|
Participants will receive intramuscular (IM) injections of Ad26.COV2.S.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Main Study: Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) S Protein Binding Antibodies Concentration Measured by Enzyme-Linked Immunosorbent Assay (ELISA) 28 Days After First Vaccination
Time Frame: 28 days after first vaccination (Day 29)
|
SARS-CoV-2 S protein binding antibodies concentration measured by ELISA will be reported.
|
28 days after first vaccination (Day 29)
|
Main Study: ELISA Geometric Mean Concentrations (GMCs) 28 Days After First Vaccination
Time Frame: 28 days after first vaccination (Day 29)
|
Non-inferiority (NI) will be assessed in terms of humoral immune response expressed by the GMCs of S-ELISA.
|
28 days after first vaccination (Day 29)
|
Main Study: SARS-CoV-2 S Protein Binding Antibodies Concentration Measured by ELISA 14 Days After Second Vaccination
Time Frame: 14 days after second vaccination (Day 71)
|
SARS-CoV-2 S protein binding antibodies concentration measured by ELISA will be reported.
|
14 days after second vaccination (Day 71)
|
Main Study: ELISA GMCs 14 Days After Second Vaccination
Time Frame: 14 days after second vaccination (Day 71)
|
NI will be assessed in terms of humoral immune response expressed by the GMCs of S-ELISA.
|
14 days after second vaccination (Day 71)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Main and Sub Study: Serological Response to Vaccination to SARS-COV-2 S Protein as Measured by ELISA
Time Frame: Up to 60 weeks
|
Serological response to vaccination to SARS-COV-2 S protein as measured by ELISA will be reported.
|
Up to 60 weeks
|
Main and Sub Study: SARS-CoV-2 S Protein Binding Antibody GMCs as Measured by ELISA or Equivalent Assay
Time Frame: Up to 60 weeks
|
SARS-CoV-2 S protein binding antibody GMCs as measured by ELISA or equivalent assay will be reported.
|
Up to 60 weeks
|
Main and Sub Study: Number of Participants with Solicited Local Adverse Events (AEs) for 7 Days After Each Vaccination
Time Frame: 7 days after first vaccination on Day 1 (up to Day 8); 7 days after second vaccination on Day 57 (up to Day 64)
|
Solicited local AEs include injection site pain/tenderness, erythema and swelling at the study vaccine injection site and the extent (largest diameter) of any erythema and swelling (using the ruler supplied) will be noted in the participant diary after 7 days after each vaccination.
|
7 days after first vaccination on Day 1 (up to Day 8); 7 days after second vaccination on Day 57 (up to Day 64)
|
Main and Sub Study: Number of Participants with Solicited Systemic AEs for 7 Days After Each Vaccination
Time Frame: 7 days after first vaccination on Day 1 (up to Day 8); 7 days after second vaccination on Day 57 (up to Day 64)
|
Solicited systemic AEs (include body temperature, fatigue, headache, nausea, myalgia) will be noted in the participant diary after 7 days of each vaccination.
|
7 days after first vaccination on Day 1 (up to Day 8); 7 days after second vaccination on Day 57 (up to Day 64)
|
Main and Sub Study: Number of Participants with Unsolicited AEs for 28 Days After Each Vaccination
Time Frame: 28 days after first vaccination on Day 1 (up to Day 29); 28 days after second vaccination on Day 57 (up to Day 85)
|
Unsolicited AEs are all AEs for which the participant is not specifically questioned in the participant diary.
|
28 days after first vaccination on Day 1 (up to Day 29); 28 days after second vaccination on Day 57 (up to Day 85)
|
Main and Sub Study: Number of Participants with Serious Adverse Events (SAEs)
Time Frame: Up to 60 weeks
|
SAE is any untoward medical occurrence that at any dose may results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, is a suspected transmission of any infectious agent via a medicinal product.
|
Up to 60 weeks
|
Main and Sub Study: Number of Participants with Adverse Events of Special Interest (AESIs)
Time Frame: Up to 60 weeks
|
Number of participants with AESIs will be reported.
Thrombosis with thrombocytopenia syndrome is considered to be an AESI.
|
Up to 60 weeks
|
Main and Sub Study: Number of Participants with Medically-Attended Adverse Events (MAAEs)
Time Frame: 6 months after second vaccination (up to 32 weeks)
|
MAAEs are defined as AEs with medically-attended visits including hospital, emergency room, urgent care clinic, or other visits to or from medical personnel for any reason.
Routine study visits will not be considered medically-attended visits.
New onset of chronic diseases will be collected as part of the MAAEs.
|
6 months after second vaccination (up to 32 weeks)
|
Main Study: Number of Participants with AEs Leading to Study Discontinuation
Time Frame: Up to 60 weeks
|
Number of participants with AEs leading to study discontinuation will be reported.
|
Up to 60 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Study Director: Janssen Vaccines & Prevention B.V. Clinical Trial, Janssen Vaccines & Prevention B.V.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
June 18, 2021
Primary Completion (Actual)
July 10, 2023
Study Completion (Actual)
July 10, 2023
Study Registration Dates
First Submitted
May 27, 2021
First Submitted That Met QC Criteria
May 27, 2021
First Posted (Actual)
June 1, 2021
Study Record Updates
Last Update Posted (Actual)
October 13, 2023
Last Update Submitted That Met QC Criteria
October 11, 2023
Last Verified
October 1, 2023
More Information
Terms related to this study
Other Study ID Numbers
- CR108960
- 2020-005801-14 (EudraCT Number)
- VAC31518COV3003 (Other Identifier: Janssen Vaccines & Prevention B.V.)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
YES
IPD Plan Description
The data sharing policy of the Janssen Pharmaceutical Companies of Johnson & Johnson is available at www.janssen.com/clinical-trials/transparency.
As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
Yes
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on COVID-19 Prevention
-
Janssen Vaccines & Prevention B.V.CompletedCOVID-19 PreventionUnited States, Belgium, Poland
-
Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.CompletedPrevention of COVID-19China
-
Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.CompletedPrevention of COVID-19China
-
Dr. Reddy's Laboratories LimitedGamaleya Research Institute of Epidemiology and Microbiology, Health Ministry... and other collaboratorsActive, not recruiting
-
Janssen Vaccines & Prevention B.V.CompletedCOVID-19 PreventionUnited States, South Africa, Brazil
-
The Cleveland ClinicCompletedPrevention of COVID-19United States
-
Gamaleya Research Institute of Epidemiology and...Russian Direct Investment FundActive, not recruitingCOVID-19 PreventionRussian Federation
-
Kenneth PalmerUnited States Department of DefenseCompleted
-
Gamaleya Research Institute of Epidemiology and...Government of the city of Moscow; Russian Direct Investment Fund; CRO: iPharmaUnknownCOVID-19 PreventionRussian Federation
-
Kenneth PalmerUnited States Department of DefenseRecruitingCOVID-19 PreventionUnited States
Clinical Trials on Ad26.COV2.S
-
Janssen Vaccines & Prevention B.V.CompletedCoronavirus Disease-2019 (COVID-19) PreventionSouth Africa, Brazil, Argentina, Mexico, India
-
Janssen Vaccines & Prevention B.V.Completed
-
Janssen Vaccines & Prevention B.V.Completed
-
Janssen Vaccines & Prevention B.V.CompletedCOVID-19 PreventionUnited States, South Africa, Brazil
-
Janssen Research & Development, LLCNo longer available
-
Centre Hospitalier Universitaire de Saint EtienneActive, not recruiting
-
University Medical Center GroningenRadboud University Medical Center; Erasmus Medical Center; Academisch Medisch... and other collaboratorsCompletedKidney Diseases | Covid19 | SARS-CoV2 Infection | Vaccine Response ImpairedNetherlands
-
Janssen Vaccines & Prevention B.V.CompletedParticipants With or Without Stable Co-morbidities Associated With Progression to Severe COVID-19United States, United Kingdom, Belgium, Spain, France, Germany, Philippines, Brazil, Colombia, South Africa
-
Janssen Vaccines & Prevention B.V.CompletedParticipants With or Without Stable Co-morbidities Associated With Progression to Severe COVID-19 at Different Stages of the ProtocolUnited States, Mexico, South Africa, Brazil, Chile, Colombia, Peru, Argentina